STOCK TITAN

Monte Rosa Therapeutics: BVF deemed owner of about 5%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. (GLUE) is the issuer in an amended beneficial-ownership report by Biotechnology Value Fund, L.P. and related reporting persons, covering positions as of September 30, 2026. Biotechnology Value Fund reported 2,243,481 shares; Biotechnology Value Fund II, L.P. reported 1,681,945 shares; and Biotechnology Value Trading Fund OS LP reported 283,767 shares.

BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 4,276,578 shares, approximately 5.0%, with shared voting and dispositive power. The report says these attributions are not, by themselves, admissions that a reporting person owns shares held by another reporting person.

Deemed beneficial ownership 4,276,578 shares BVF Partners L.P., BVF Inc. and Mark N. Lampert; as of September 30, 2026
Percent of class approximately 5.0% BVF Partners L.P., BVF Inc. and Mark N. Lampert; as of September 30, 2026
BVF beneficial ownership 2,243,481 shares Biotechnology Value Fund, L.P.; as of September 30, 2026
BVF II beneficial ownership 1,681,945 shares Biotechnology Value Fund II, L.P.; as of September 30, 2026
Trading Fund OS beneficial ownership 283,767 shares Biotechnology Value Trading Fund OS LP; as of September 30, 2026
Deemed beneficial ownership 3,925,426 shares BVF GP Holdings LLC; as of September 30, 2026
Shares outstanding 85,313,401 shares Basis for ownership percentages; as of July 31, 2026
beneficially owned regulatory
"BVF beneficially owned 2,243,481 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared voting power over the Shares"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power over the Shares"
Partners Managed Account financial
"Shares held in the Partners Managed Account"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share count was used to calculate the GLUE ownership percentages?

The ownership percentages are based on 85,313,401 shares outstanding as of July 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





61225M102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading